Advertisement

Rheumatology International

, Volume 31, Issue 6, pp 785–794 | Cite as

Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis

  • Xue Qin
  • Yan Deng
  • Jing Xu
  • Tai-Jie Li
  • Shan LiEmail author
  • Jin-Min ZhaoEmail author
Original Article

Abstract

Conventional tests are not always helpful in making a diagnosis of rheumatoid arthritis (RA). This study aimed to comprehensively and quantitatively summarize the evidence on the accuracy of anti-mutated citrullinated vimentin (MCV) assay in the diagnosis of RA. A comprehensive meta-review of data on the accuracy of MCV concentrations in the diagnosis of RA were carried out from 16 published studies. Furthermore, receiver operating characteristic curves were used to summarize the overall test performance. The summary estimates for MCV in the diagnosis of RA were: sensitivity 0.77 [95% confidence interval (CI) 0.75–0.78], specificity 0.89 (95% CI 0.87–0.90), positive likelihood ratio (LR+) 7.24 (95% CI 5.60–9.36), negative likelihood ratio (LR−) 0.28 (95% CI 0.23–0.34) and diagnostic odds ratio 29.66 (95% CI 21.09–41.71). The area under the summary receiver operating characteristic curves was 0.92. Data from meta-analysis suggest the accuracy of MCV assay in the diagnosis of RA is high, but ultimately clinician must consider the results of MCV tests combing with other conventional examinations and the clinical feature.

Keywords

Meta-analysis Accuracy Diagnosis Mutated citrullinated vimentin Rheumatoid arthritis 

Notes

Conflict of interest statement

None declared. The views expressed in this paper are those of the authors and not necessarily those of any funding body.

References

  1. 1.
    Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799PubMedCrossRefGoogle Scholar
  2. 2.
    Wei GL, Ding Y, Han YX, Chen JL, Xu LH, Yong YH, Yang ZY (2008) Preparation of ELISA kit for quantitative determination of antibody against cyclic citrullinated peptide and its significance in diagnosis of rheumatoid arthritis. Chin J Biologicals 21:421–424Google Scholar
  3. 3.
    Huizinga TW, MacHold KP, Breedveld FC, Lipsky PE, Smolen JS (2002) Criteria for early rheumatoid arthritis: from Bayes’ law revisited to new thoughts on pathogenesis. Arthritis Rheum 46:1155–1159PubMedCrossRefGoogle Scholar
  4. 4.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRefGoogle Scholar
  5. 5.
    Saraux A, Berthelot JM, Chalès G, Le Henaff C, Mary JY, Thorel JB, Hoang S, Dueymes M, Allain J, Devauchelle V, Baron D, Le Goff P, Youinou P (2002) Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 47:155–165PubMedCrossRefGoogle Scholar
  6. 6.
    Cruyssen BV, Cantaert T, Nogueira L, Clavel C, Rycke LD, Dendoven A, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F (2006) Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 8:R122CrossRefGoogle Scholar
  7. 7.
    Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G (1995) The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 95:2672–2679PubMedCrossRefGoogle Scholar
  8. 8.
    Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessière C, Jolivet-Reynaud C, Jolivet M, Serre G (1999) The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 162:585–594PubMedGoogle Scholar
  9. 9.
    Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J Clin Invest 101:273–281PubMedCrossRefGoogle Scholar
  10. 10.
    Herold M, Boeser V, Russe E, Klotz W (2005) Anti-CCP: history and its usefulness. Clin Dev Immunol 12:131–135PubMedCrossRefGoogle Scholar
  11. 11.
    Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing acyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRefGoogle Scholar
  12. 12.
    Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRefGoogle Scholar
  13. 13.
    Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chalès G, Le Henaff C, Thorel JB, Hoang S, Jousse S, Baron D, Le Goff P, Youinou P (2003) Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 30:2535–2539PubMedGoogle Scholar
  14. 14.
    Vossenaar ER, Venrooij WJ (2004) Anti-CCP antibodies, a specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 4:239–262CrossRefGoogle Scholar
  15. 15.
    Takasaki Y, Yamanaka K, Takasaki C, Matsushita M, Yamada H, Nawata M, Matsudaira R, Ikeda K, Kaneda K, Hashimoto H (2004) Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 14:367–375PubMedCrossRefGoogle Scholar
  16. 16.
    Vannini A, Cheung K, Fusconi M, Stammen-Vogelzangs J, Drenth JP, Dall’Aglio AC, Bianchi FB, Bakker-Jonges LE, van Venrooij WJ, Pruijn GJ, Zendman AJ (2007) Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis 66:511–516PubMedCrossRefGoogle Scholar
  17. 17.
    Despres N, Boire G, Lopez-Longo FJ, Ménard HA (1994) The Sa system: a novel antigen–antibody system specific for rheumatoid arthritis. J Rheumatol 21:1027–1033PubMedGoogle Scholar
  18. 18.
    El-Gabalawy HS, Wilkins JA (2004) Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther 6:86–89PubMedCrossRefGoogle Scholar
  19. 19.
    Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, van Venrooij WJ, Ménard HA (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6:R142–R150PubMedCrossRefGoogle Scholar
  20. 20.
    Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Ménard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR Jr, El-Gabalawy HS (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2(3):236–243PubMedCrossRefGoogle Scholar
  21. 21.
    Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8:119CrossRefGoogle Scholar
  22. 22.
    Devillé WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9PubMedCrossRefGoogle Scholar
  23. 23.
    Whiting P, Rutjes AW, Reitsma JB, Reitsma J, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25PubMedCrossRefGoogle Scholar
  24. 24.
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129–1135PubMedCrossRefGoogle Scholar
  25. 25.
    Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12:1293–1316PubMedGoogle Scholar
  26. 26.
    Deeks JJ (2001) Systematic reviews of evaluation of diagnostic and screening tests. In: Egger M, Davey-Smith G, Altmann DG (eds) Systematic reviews in health care: meta-analysis in context. BMJ, London, pp 248–282Google Scholar
  27. 27.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  28. 28.
    Suzuki S, Moro-oka T, Choudhry NK (2004) The conditional relative odds ratio provided less biased results for comparing diagnostic test accuracy in meta-analyses. J Clin Epidemiol 57:461–469PubMedCrossRefGoogle Scholar
  29. 29.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  30. 30.
    Coenen D, Verschueren P, Westhovens R, Bossuyt X (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 53:498–504PubMedCrossRefGoogle Scholar
  31. 31.
    Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658–1663PubMedGoogle Scholar
  32. 32.
    Bang H, Egerer K, Gauliard A, Lüthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511PubMedCrossRefGoogle Scholar
  33. 33.
    Bizzaro N, Tonutti E, Tozzoli R, Villalta D (2007) Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 53:1527–1533PubMedCrossRefGoogle Scholar
  34. 34.
    Song JS, Park GB, Park AJ (2007) Comparison of anti-mutated citrullinated vimentin with anti-cyclic citrullinated peptide and rheumatoid factors for the diagnostic value of rheumatoid arthritis. Korean Rheum Assoc 14:235–241CrossRefGoogle Scholar
  35. 35.
    Poulsom H, Charles PJ (2008) Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol 34:4–10PubMedCrossRefGoogle Scholar
  36. 36.
    Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1002–1008PubMedGoogle Scholar
  37. 37.
    Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BA, Hamann D (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:12CrossRefGoogle Scholar
  38. 38.
    Mathsson L, Mullazehi M, Wick MC, Sjöberg O, van Vollenhoven R, Klareskog L, Rönnelid J (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36–45PubMedCrossRefGoogle Scholar
  39. 39.
    Wagner E, Skoumal M, Bayer PM, Klaushofer K (2009) Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatol Int. Available at http://www.springerlink.com/content/8232g31958731036/ (published online)
  40. 40.
    Mutlu N, Bicakcigil M, Tasan DA, Kaya A, Yavuz S, Ozden AI (2009) Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J of Rheum 36:491–500CrossRefGoogle Scholar
  41. 41.
    Feng R, YZ LI, Zhao GF, Jiang M (2006) The diagnostic value of anti-mutated citrullinated vimentin antibody in patients with rheumatoid arthritis. Chin J Rheumatol 10:686–689Google Scholar
  42. 42.
    Jiang YM, Jiang DL, Pan YH, Sun JM (2008) Diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Clin Focus 23:1160–1162Google Scholar
  43. 43.
    Xu HP, Qi WC, Qi WF (2008) The diagnostic value of the antibodies against mutated citrullinated vimentin in patients with rheumatoid arthritis. Tianjin Med J 36:676–678Google Scholar
  44. 44.
    Song JR, Yu QH (2008) The early diagnostic value of the antibodies against mutated citrullinated vimentin in patients with rheumatoid arthritis. Sheng Yang Bu Dui Yi Yao 21:305–306Google Scholar
  45. 45.
    Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Ménard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR Jr, El-Gabalawy HS (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2:236–243PubMedCrossRefGoogle Scholar
  46. 46.
    Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, Trang L (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 22:2208–2213PubMedGoogle Scholar
  47. 47.
    Quinn MA, Emery P (2005) Potential for altering rheumatoid arthritis outcome. Rheum Dis Clin North Am 31:763–772PubMedCrossRefGoogle Scholar
  48. 48.
    Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMedGoogle Scholar
  49. 49.
    Deeks JJ (2001) Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 323:157–162PubMedCrossRefGoogle Scholar
  50. 50.
    Irwig L, Tosteson AN, Gatsonis C, Lau J, Colditz G, Chalmers TC, Mosteller F (1994) Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med 120:667–676PubMedGoogle Scholar
  51. 51.
    Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463PubMedCrossRefGoogle Scholar
  52. 52.
    Petitti DB (2001) Approaches to heterogeneity in meta-analysis. Stat Med 20:3625–3633PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of Clinical LaboratoryFirst Affiliated Hospital of Guangxi Medical UniversityNanningChina
  2. 2.Evidence-Based Medicine Center of GuangxiFirst Affiliated Hospital of Guangxi Medical UniversityNanningChina
  3. 3.Department of Orthopaedic Trauma SurgeryFirst Affiliated Hospital of Guangxi Medical UniversityNanningChina

Personalised recommendations